Endologix, Inc. (NASDAQ:ELGX) was down 10.2% on Thursday . The company traded as low as $5.66 and last traded at $5.75. Approximately 670,700 shares were traded during mid-day trading, an increase of 9% from the average daily volume of 616,955 shares. The stock had previously closed at $6.40.
A number of equities research analysts have weighed in on ELGX shares. BidaskClub upgraded Endologix from a “hold” rating to a “buy” rating in a research report on Thursday, May 3rd. ValuEngine upgraded Endologix from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research upgraded Endologix from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. Oppenheimer set a $5.00 target price on Endologix and gave the stock a “hold” rating in a research report on Thursday, May 3rd. Finally, Stifel Nicolaus upped their target price on Endologix from $4.50 to $5.00 and gave the stock a “hold” rating in a research report on Monday, May 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Endologix presently has an average rating of “Hold” and an average target price of $4.95.
The stock has a market capitalization of $483.06 million, a price-to-earnings ratio of -12.21 and a beta of 0.44. The company has a debt-to-equity ratio of 3.58, a current ratio of 2.13 and a quick ratio of 1.37.
Endologix (NASDAQ:ELGX) last released its earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Endologix had a negative return on equity of 47.01% and a negative net margin of 35.86%. The firm had revenue of $42.28 million during the quarter, compared to the consensus estimate of $41.14 million. During the same period in the prior year, the firm posted ($0.18) earnings per share. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. research analysts forecast that Endologix, Inc. will post -0.7 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the company. Lake Street Advisors Group LLC acquired a new stake in shares of Endologix during the 4th quarter valued at $120,000. Teacher Retirement System of Texas acquired a new stake in shares of Endologix during the 4th quarter valued at $144,000. MetLife Investment Advisors LLC acquired a new stake in shares of Endologix during the 4th quarter valued at $236,000. Millrace Asset Group Inc. acquired a new stake in shares of Endologix during the 4th quarter valued at $669,000. Finally, Deutsche Bank AG lifted its position in shares of Endologix by 111.7% during the 4th quarter. Deutsche Bank AG now owns 190,868 shares of the medical instruments supplier’s stock valued at $1,019,000 after acquiring an additional 100,703 shares during the last quarter. Institutional investors own 97.11% of the company’s stock.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.